To determine whether the use of the C-Pulse(R) System, as a treatment for patients in moderate to severe heart failure (HF) has demonstrated safety and efficacy, such that the C-Pulse(R) System merits Food and Drug Administration (FDA) approval to market the device in the US. The C-Pulse(R) system is intended to relieve the symptoms of heart failure, improve quality of life and cardiac function, and reduce the need for heart failure hospitalization. It is intended for use in hospital and at home
Who may be Eligible
Patients must have a left ventricular ejection fraction (LVEF) = 35%, must be greater than 18 years of age, and must be on stable medical therapy, among other entry criteria. The study doctor(s) can provide additional information regarding study eligibility.